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Abstract
Bacterial resistance to antibiotics has become a major source of concern for public health. Enterobacteriaceae are among the most common human
pathogens, causing community-acquired as well as hospital-acquired infections. Carbapenem-resistant Enterobacteriaceae have been increasingly
reported worldwide since their ﬁrst identiﬁcation more than 20 years ago. Three main classes of carbapenemases have been identiﬁed: Ambler
class A beta-lactamase (KPC), class B (metallo-enzymes), and class D (OXA-48 type). Klebsiella  pneumoniae  carbapenemases (KPC) was ﬁrst
reported in the United States in the late 1990s and since then worldwide, with a marked endemicity in the United States, Greece, and now Italy.
Carbapenemase NDM-1 (New Delhi metallo-beta-lactamase-1) is one of the most recently reported metallo-enzymes. It has spread widely in the
Indian sub-continent and now worldwide. Carbapenemases of the oxacillinase-48 type (OXA-48) have been identiﬁed mostly in Mediterranean
and southern European countries with a rapid spread. An early and quick identiﬁcation of carbapenemase-producing infected patients, but also of
carriers, is mandatory to prevent the spread of these highly resistant pathogens. The early identiﬁcation of carriers and implementing of cohorting
strategies is the only means to prevent nosocomial outbreaks caused by carbapenemase, with very few, if any, therapeutic options.
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carbapenemase
Résumé
La résistance bactérienne aux antibiotiques est d’incidence croissante notamment parmi les entérobactéries qui sont les bactéries pathogènes
les plus fréquentes pour l’Homme et sont la source de nombreuses infections communautaires et nosocomiales. Des entérobactéries résistantes
aux carbapénèmes ont été rapportées avec une fréquence croissante dans le monde depuis leur première description il y a plus de 20 ans. Trois
principales classes de carbapénémases ont été décrites : classe A (KPC), classe B (métallo-enzymes) et classe D (OXA-48). Depuis leur première
description aux États-Unis à la ﬁn des années 1990, les carbapénémases Klebsiella  pneumoniae  (KPC) ont été observées sur les cinq continents. La
plus forte endémicité se situe aux États-Unis, en Grèce, et plus dernièrement en Italie. Parmi les carbapénémases du groupe des métallo-enzymes,
New Delhi metallo-beta-lactamase-1 (NDM-1) est de description plus récente. Elle a une prévalence très élevée dans l’ensemble du sous-continent
indien. Les carbapénémases de type oxacillinase-48 (OXA-48) ont été rapportées essentiellement dans le pourtour de la Méditerranée et en
Europe du Sud où leur diffusion est particulièrement rapide. Pour prévenir l’extension de la diffusion de ces bactéries pathogènes multirésistantes,
l’identiﬁcation précoce et rapide des sujets infectés, mais aussi des patients porteurs, devient une nécessité. Elle permet la mise en œuvre d’une
stratégie d’isolement par cohorting  qui représentent l’unique moyen d’éviter la propagation d’épidémies nosocomiales causées par des souches
productrices de carbapénémases, pour lesquelles les possibilités thérapeutiques sont limitées.
Mots clés : Entérobactéries ; Carbapénémases ; Métallo--lactamase ; Oxacillinase-48 ; New Delhi metallo-beta-lactamase-1 ; Klebsiella pneumoniae carbapénémase
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Bacterial resistance to antibiotics has become a major source
of concern for public health. The reality of this menace was
fully acknowledged by world decision makers in 2013 at the
Davos Economic Forum (Switzerland). With as subtitle “Health
and hubris”, the global press release at the end of this forum
presents the size of the risk in the following terms “Huge strides
forward in health have left the world dangerously complacent.
Rising resistance to antibiotics could push overburdened health
systems to the brink, while a hyper-connected world allows
pandemics to spread. This risk case draws on the connections
between antibiotic resistance, chronic disease and the failure
of the international intellectual property regime, recommending
more international collaboration and different funding models”.
The risk for Europe was assessed ﬁnancially at 1.5 billion euros.
The severity of this menace is ampliﬁed by the fact that research
for new antibiotic agents is currently stalled. It may be possible
that no totally new agent active against multiresistant bacteria
will be put on the market in a close future. The 20th century was
“the century of antibiotics”, marked by the discovery and the
continuous development of new more and more active antibi-
otics, but no new family has been available for clinicians since
lipopeptides in 1987.
Virologists have discovered numerous viruses in the previous
3 decades: HIV, hepatitis virus, SARS, or the new ﬂu viruses;
at the same time many agents active on some of these viruses
were developed and the antiviral therapeutic arsenal has never
stopped growing. Conversely, in bacteriology, we have selected
strains resistant to all antibiotics among the most frequent bac-
terial species — Enterobacteriaceae — without being able to
develop agents capable of destroying them or effective strate-
gies to prevent their extension. These carbapenemase-producing
Enterobacteriaceae are progressively spreading throughout the
world [1].
1. General  features  and  classiﬁcation
The enterobacterial carbapenemases differ from the extended
spectrum beta-lactamases (ESBL) which include (CTX-M),
which hydrolyze or inactivate the beta-lactams and 2nd and
3rd generation cephalosporins, but not carbapenems. Most car-
bapenemases hydrolyze beta-lactams and cephalosporins, but
also monobactams and carbapenems, so that no beta-lactam can
remain effective (Fig. 1).
The Ambler classiﬁcation proposed in 1980 is based on analo-
gies of the peptide sequence; beta-lactamases are classiﬁed in 4
groups, A to D. Groups A, C, and D enzymes are serine-enzymes,
while those of group B are metallo-enzymes. Carbapenemases
mainly belong to 3 great groups of beta-lactamases, A, B, and D,
the differences of which have not only a genetic and biochemical
interest, but also a clinical one, because the proﬁle of resistance
and the epidemiology of these strains differ.
The ﬁrst group, called Ambler class A, is that of penicilli-
nases. The most common is KPC (Klebsiella  pneumoniae  car-
bapenemase), but there are others, such as Serratia  Marcescens
(SME), non-metallo carbapanemase (NMC), imipenemase
(IMI), Guyana extended-spectrum-lactamase (GES), etc. First
identiﬁed in the 1980s, they are enzymes the activity spectrum
Fig. 1. Activity spectrum of carbapenemases in Enterobacteriaceae.
Spectre d’activité des carbapénémases des entérobactéries.
of which extends to carbapenems. They remain inhibited, at least
in vitro, by beta-lactamase inhibitors, especially clavulanic acid.
The second group, class B, is that of metallo-proteins, one
of the latest of with a large spread is NDM-1. These metallo-
proteins hydrolyze all antibiotics, except aztreonam. The third
group, class D, is that of oxacillinases, OXA-48 derivatives.
They hydrolyze penicillins, 1st generation cephalosporins, and
carbapenems; they are resistant to beta-lactamase inhibitors, and
weakly active against 2nd and 3rd generation cephalosporins
such as cefotaxime or ceftazidime, and hydrolyze only partly
carbapenems.
None of the beta-lactamase inhibitors currently available, nor
even the new inhibitors under development, allow inhibiting the
3 groups of carbapenemases.
2. Group  of  penicillinases:  KPC
The term KPC, for K.  pneumoniae  carbapenemase, is rela-
tively inadequate because these are enzymes the genes of which
transfer very easily from an enterobacterium to another, what-
ever the type, and thus are not limited to K.  pneumoniae. The
strains expressing KPC are resistant to all beta-lactams, but also
resistant to most of the other antibiotics families.
Class A carbapenemases have been identiﬁed sporadically
in clinical isolates clinical since the 1980s; they were most
often chromosomal enzymes. A strain carrying a plasmid car-
bapenemase, KPC-1, was ﬁrst observed in North Carolina in
1996 [2]. KPC strains remained rare in the USA until 2005,
when KPC-producing Enterobacteriaceae were identiﬁed in out-
breaks, in several New York and New Jersey hospitals. A spread
was then observed throughout North America [3,4]. In 2012,
more than 1,200 strains of K.  pneumoniae  producing KPC type
enzymes were isolated from blood cultures in a New York teach-
ing hospital, proving their large spread (P. Nordmann, personal
communication). This menace has now been taken into account
at the highest level in the USA where major research grants
have been attributed by the federal authorities to ﬁght against
this major public healthcare challenge.
KPC strains have spread largely, as all enteric bacteria, via
colonized patients and air transportation [5]. After the East
coast of the USA, KPC plasmid strains were isolated almost
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everywhere in the world: in France for the ﬁrst time in 2005 in
a patient coming back from New York where he had undergone
bilateral nephrostomy [6]; in Israel [7,8]; in China and Taiwan
[9,10]; in South America: in Columbia in a Pseudomonas
aeruginosa strain [11], in Brazil [12,13], in Argentina [14]. . .)
and of course in most European countries [15]. The main
endemic focus in Europe is located in Greece [15–17]. Italy,
affected shortly after Greece, comes second [18], but Scotland
[19], Germany [20], Belgium [21], Finland [22], Scandinavian
countries [23], Switzerland [24] are also affected, via Greece
and Italy most often. Most of the colonized patients reported in
France come from Italy [25]. Nevertheless, at this time, there
are few epidemic foci in France and their extension is limited.
There are many circulating strains, even if some clones are
rather predominant, especially ST type ST-258. The genes car-
rying resistance enzymes are located on transposons, which give
them an additional degree of bacterial plasticity [26].
3. Metallo-enzymes
One of the currently best known metallo-beta-lactamases
is NDM-1 (for New Delhi metallo-beta-lactamase), described
for the ﬁrst time in 2009 in a Swedish patient of Indian ori-
gin, hospitalized in Sweden after coming back from New Delhi
[27]. The K.  pneumoniae  strain was isolated in urine. The NDM
strains are usually resistant to almost all antibiotics, except
to tigecycline and colistin. British authors were able to deter-
mine that the main reservoirs of these resistant strains were
located in the Indian sub-continent: India, Pakistan, Bangladesh,
and Sri Lanka. These beta-lactamases were later identiﬁed
in various species of Enterobacteriaceae: not only Klebsiella,
but also Escherichia  coli, the most frequent of community-
acquired Enterobacteriaceae, in Acinetobacter  baumannii, then
in P.  aeruginosa. A signiﬁcant spread, even if more limited, was
observed in Great Britain, which has close bonds with India
and Pakistan [28,29]. The publication of these results was con-
sidered as possibly detrimental for the Indian economy, since
managing foreign patients is an important source of revenue.
A British television journalist collected samples in New Delhi
at water delivery points. The analysis of these samples proved
that tap water (including drinkable tap water) and rainwater con-
tained bacteria carrying NDM-1, not only Enterobacteriaceae,
Stenotrophomonas maltophilia, and Pseudomonas  strains, but
also choleric vibrions [30].
Why did these strains appear in the Indian sub-continent and
now reached such a high prevalence? In fact, all the factors
possibly promoting this emergence can be found.
First, strong selection pressure: all antibiotics are sold freely
in India and their use is rarely controlled. India is today the ﬁrst
nation for the production of generic drugs in the world. Generic
ertapenem and imipenem manufactured locally are easily avail-
able. The reported  consumption of  carbapenems per capita in
India is 8 times higher than that of the Netherlands; the true
consumption is probably 25 times higher.
Second, the environment is characterized by the non-respect
of elementary hygiene rules, especially concerning water. A
great proportion of people present with chronic diarrhea and
the mortality due to intestinal infections is one of the highest in
the world.
Third, the transmission and spread of strains is promoted by
over-population: 1.4 billion people live in India in slightly more
than 3 million km2, 6 times the size of France. This promiscuity
enhances the risks of person-to-person transmission of intestinal
bacteria. The high temperatures and high humidity are especially
favorable for bacterial overgrowth, especially in the south of the
country.
The spread of strains in the community is important, so that
colonization of travellers is possible even if they were not in
direct contact with healthcare. The spread of carbapenemase-
producing strains is currently massive in the Indian sub-
continent: the prevalence of carriage is estimated at 5 to 15%
[31].
The impact of intercontinental travels is well illustrated
by the epidemiology: the spread of NDM-1 strains overlaps
almost exactly the contours of the old British Empire where
many Indian or Pakistani expatriate live: Great Britain, Canada,
the USA, South Africa, Kenya, Saudi Arabia, Gulf countries,
Malaysia, Australia, etc. [32,33]. This is the case especially
in English-speaking Africa whereas French-speaking regions
are still relatively not affected, likewise in Spanish-speaking
countries of South America.
In Europe and especially in France, several NDM-1 strains,
most coming from the Indian reservoir, have been identiﬁed
[34,35]. Even if the rare NDM-1 strains identiﬁed in France
are not a public healthcare challenge yet, the emergence of
K. pneumoniae  NDM-1 strains without any link with the Indian
sub-continent has already been reported in France and in
Morocco [36,37]. Is this an isolated phenomenon or the begin-
ning of a broader spread of these strains? A worldwide spread of
these NDM strains, similar to those observed within a few years
for the ESBL producing strains of the CTX-M type would be a
catastrophe.
Besides K.  pneumoniae  and E.  coli, NDM producing strains
have been identiﬁed in many bacterial species: Enterobacter,
Serratia, Citrobacter, Pseudomonas, Acinetobacter, etc. These
are not particularly virulent strains; asymptomatic carriage may
persist for more than a year, but severe invasive, septicemia
or neurosurgical infections may develop and raise unsolvable
therapeutic issues.
The may concern with NDM resistance is that it is now
carried by E.  coli, ubiquitous and non-nosocomial bacterium,
the most frequent of all bacteria, the ﬁrst pathogen responsible
for community-acquired infections, the ﬁrst cause of urinary
tract infections and bacterial diarrhea [28]. Controlling such
community-acquired bacteria is almost impossible. A hospital
can be closed but not community life.
Genetically, these strains can associate up to 20 determinants
of chromosomal plasmid resistance [38].
4. Group  of  OXA-48-type  oxacillinases
Oxacillinases (Ambler class D) account for the greatest
number of multiresistant strains currently detected in France.
The genes come from plasmids and strains may host several
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Fig. 2. Worldwide spread of OXA-48 producing strains.
Diffusion des souches OXA-48 dans le monde.
resistance genes, especially OXA-48 and CTX-M. The contam-
ination reservoir is in this case much closer to France, in North
Africa, Libya, Egypt, the Middle East, and Turkey. There are
increased risks related to political and sanitary upheavals in these
countries (Fig. 2). The historical and political bonds between
France and these nations explain the important spread of these
strains in our country.
The OXA-48 gene is very unusually (in bacteriology) most
often located on a single plasmid, which has spread in many
different Enterobacteriaceae strains and species [39].
5. Avoiding  the Italian  scenario
In 2012, the French National Reference Center (Bicêtre) iden-
tiﬁed 343 strains producing a carbapenemase among the 1,485
strains received with a more or less marked resistance to car-
bapenems. Most of them were Klebsiella, but also E.  coli  (Fig. 3).
This evolution is a matter of concern since it proves the extra-
hospital spread. Resistance is primarily of the OXA-48 type
(75%), and less frequently KPC (12%) and NDM (8%). Car-
bapenemases Verona imipenemase (VIM) (5%) and IMI (<1%)
remain a minority.
The objective for France is to avoid the Italian scenario,
where was observed in 2010 the very rapid spread of resistant
strains (source: European Center for Disease Prevention and
Control; Antimicrobial resistance surveillance in Europe 2010.
Annual report. EARS-Net. ECDC, 2011). Before, in 2009,
these strains were isolated almost exclusively in Greece, and
in 2010 the rate of resistant strains rose from less than 5%
to more than 10 and 25%, within a year. All Italian hospitals
— in Rome, Milan, Verona, Venice — now have to face the
endemicity of KPC strains [15]. It is thus most important that
any patient hospitalized in Italy be screened on admission in
the French hospital system [40].
6. Rapid diagnosis
The implementation of screening and isolation measures is
all the more effective if the diagnosis of colonization is made
early. The Carba NP test, a rapid diagnostic test, was developed
by our team [41]. It is a simple colorimetric test that identi-
ﬁes any carbapenemase activity. The technique is very easy to
implement and does not require molecular biology. Hence it is
cheap (2 to 3 euros) and may be developed in any country or
structure with limited resources. The result is obtained in less
than 2 hours, with a speciﬁcity and a sensitivity of 100%, which
is rare for a biological test. The Carba NP test has been adopted
Fig. 3. Carbapenemase-producing strains in France in 2012.
Souches productrices de  carbapénémases en France en  2012.
French National Reference Center, Bicêtre
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already in several countries, France, Singapore, Hong Kong,
Italy, Belgium, Great Britain, Germany, Switzerland, the Mayo
Clinic (USA), etc.
7. Perspectives
Even if we refuse to consider the catastrophe scenario, the
prospects for antibiotherapy in the next 3 years are relatively
pessimistic. Contrary to what was observed for Staphylococcus
aureus, the reversion of Enterobacteriaceae resistance seems to
be extremely rare or null. What may be feared is the evolu-
tion from multiple resistances to panresistance. And there is
a well-demonstrated relationship between antibiotic resistance
and increased mortality of infection. Furthermore, the aging
population, the development of intensive care, of organ trans-
plantations, of anticancerous treatments are all factors leading
to an increase of immunodepression, making patients ideal tar-
gets for carbapenemase-producing Enterobacteriaceae. These
are evolving from the status of strictly nosocomial to that of
community-acquired bacteria, rendering no-effective isolation
measures applied only on healthcare institutions.
Policies for the controlled use of anti-infectious drugs remain
mandatory to try to stop the hospital spread of these multiresis-
tant bacteria, but hygiene measures at the source of prevention of
cross transmission are capital. All hospitalized patients coming
from a foreign country than transferred to the French health-
care system should be screened. Cohorting procedures should
be implemented as early as possible and very strictly as soon
as they are indicated. It is highly probable that specialized units
will soon have to be set up in the large hospitals, with a strict
geographic separation and dedicated personnel. These multidrug
resistant bacteria should be managed like the SARS virus or ﬂu
mutants; it is a public healthcare obligation. These multidrug
resistant bacteria should be considered with the utmost cau-
tion, even if Enterobacteriaceae bacterial species are well known
(E. coli, K.  pneumoniae, etc.) and belong for the greater number
to the commensal ﬂora.
The  dangers  of  hubris  on human  health
Health is a critical  system  that  is  constantly
being challenged,  be  it by emerging  pandemics
or chronic  illnesses.  Scientiﬁc  discoveries  and
emerging technologies  allow  us  to  face  such
challenges, but  the  medical  successes  of  the  past
century may  also  be  creating  a false  sense  of
security. Arguably,  one of  the  most  effective  and
common means  to protect  human  life  – the  use
of antibacterial  and antimicrobial  compounds
(antibiotics) –  may  no longer  be  readily  available
in the  near  future.  Every  dose  of  antibiotics
creates selective  evolutionary  pressures,  as  some
bacteria survive  to  pass  on  the  genetic  mutations
that enabled  them  to  do so. Until  now,  new
antibiotics have  been  developed  to replace  older,
increasingly  ineffective  ones.  However,  human
innovation may no  longer  be outpacing  bacte-
rial mutation.  None  of  the  new  drugs  currently  in
the development  pipeline  may be effective  against
certain new mutations  of  killer  bacteria  that  could
turn into  a pandemic.  Are  there  ways  to  stimu-
late the  development  of  new  antibiotics  as  well  as
align incentives  to  prevent  their overuse,  or  are
we in  danger of  returning  to a pre-antibiotic  era  in
which a scratch  could  be potentially fatal?
Global Risks 2013 report  of  the World Economic Forum. Full
report  available at http://www.weforum.org/globalrisks2013.
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